SRNE – Sorrento Therapeutics, Inc.
Float Short %
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
EPS Last/This Y
EPS This/Next Y
Price
0.01
Target Price
13
Analyst Recom
2.5
Performance Q
-46.77
Upside
N/A
Beta
Ticker: SRNE
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-01-23 | SRNE | 0.0035 | N/A | N/A | 0 |
| 2026-01-26 | SRNE | 0.0035 | N/A | N/A | 0 |
| 2026-01-27 | SRNE | 0.004 | N/A | N/A | 0 |
| 2026-01-28 | SRNE | 0.0007 | N/A | N/A | 0 |
| 2026-01-29 | SRNE | 0.0025 | N/A | N/A | 0 |
| 2026-01-30 | SRNE | 0.0025 | N/A | N/A | 0 |
| 2026-02-02 | SRNE | 0.0028 | N/A | N/A | 0 |
| 2026-02-03 | SRNE | 0.0025 | N/A | N/A | 0 |
| 2026-02-05 | SRNE | 0.0025 | N/A | N/A | 0 |
| 2026-02-09 | SRNE | 0.0013 | N/A | N/A | 0 |
| 2026-02-10 | SRNE | 0.0013 | N/A | N/A | 0 |
| 2026-02-11 | SRNE | 0.0013 | N/A | N/A | 0 |
| 2026-02-12 | SRNE | 0.0014 | N/A | N/A | 0 |
| 2026-02-13 | SRNE | 0.0025 | N/A | N/A | 0 |
| 2026-02-17 | SRNE | 0.0017 | N/A | N/A | 0 |
| 2026-02-18 | SRNE | 0.0025 | N/A | N/A | 0 |
| 2026-02-19 | SRNE | 0.0016 | N/A | N/A | 0 |
| 2026-02-20 | SRNE | 0.0028 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
No data found
No data found
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
Avg. EPS Est. Next Quarter
Insider Transactions
Institutional Transactions
Beta
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
12
Growth Score
Sentiment Score
94
Actual DrawDown %
Max Drawdown 5-Year %
Target Price
13
P/E
Forward P/E
PEG
P/S
P/B
P/Free Cash Flow
EPS
Average EPS Est. Cur. Y
EPS Next Y. (Est.)
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
Return on Equity vs Sector %
243.9
Return on Equity vs Industry %
216.3
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
Sorrento Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 949
Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, provides therapeutic solutions in the United States and internationally. It offers chimeric antigen receptor T-cell therapy, dimeric antigen receptor T-cell therapy, and antibody-drug conjugates, as well as Seprehvec, SOFUSA, RTX, and SEMDEXA. The company also develops antiviral therapies and vaccines, including Abivertinib, COVI-MSC, COVI-AMG, COVIDROPS, and COVI SHIELD; and diagnostic test solutions, such as COVISTIX, COVITRACK, and Virex. Its products are used for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases treatment. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.
stock quote shares SRNE – Sorrento Therapeutics, Inc. Stock Price stock today
news today SRNE – Sorrento Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch SRNE – Sorrento Therapeutics, Inc. yahoo finance google finance
stock history SRNE – Sorrento Therapeutics, Inc. invest stock market
stock prices SRNE premarket after hours
ticker SRNE fair value insiders trading